我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1976
已完成
100.0%
暂无批准数据
- Pykus Therapeutics has completed enrollment for its PYK-2101 pilot study in Australia, testing a first-in-class biodegradable retinal hydrogel sealant for retinal detachment surgery. - The innovative treatment aims to eliminate the need for post-operative face-down positioning and intraocular gas, potentially transforming patient recovery and surgical outcomes. - The company plans to submit an Investigational Device Exemption application to the FDA in Q4 2025 for a U.S. pivotal trial, with interim study results expected in Q2 2025.
